In this issue:
Azacitidine for intermediate-2 or high-risk MDS
ELN recommendations for AML diagnosis and management
BDR in newly diagnosed Waldenström’s macroglobulinaemia
Novel allogeneic transplant protocol for severe aplastic anaemia
Long-term follow-up of stopping imatinib in CML (STIM1)
JAK2 inhibitor for myelofibrosis
JAK 2V617F and CALR mutations in recurrent VTE
Comparisons of VTE prophylaxis options for total hip/knee replacement
Statins reduce VTE risk
Please login below to download this issue (PDF)